Ubrogepant: First Approval
Lesley J. Scott
Abstract
Ubrogepant (Ubrelvy™) is an orally administered, small molecule, highly-selective, calcitonin gene-related peptide (CGRP) antagonist that was developed by Allergan under license to Merck & Co. as an acute treatment for migraine. In December 2019, ubrogepant received its first global approval in the USA for the acute treatment of migraine (± aura) in adults. This article summarizes the milestones in the development of ubrogepant leading to its first global approval for the acute treatment of migraine (± aura) in adults.
Topics & Concepts
MedicineMigraineCalcitonin gene-related peptideAuraSumatriptanDrug approvalInvestigational DrugsPharmacologyInternal medicineDrugClinical trialAgonistNeuropeptideReceptorMigraine and Headache StudiesAttention Deficit Hyperactivity DisorderSuicide and Self-Harm Studies